Preferred Label : Fadraciclib;
NCIt synonyms : Cyclin Dependent Kinase Inhibitor 2/5/9 CYC065;
NCIt definition : An orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9),
with potential antineoplastic and chemoprotective activities. Upon oral administration,
fadraciclib selectively binds to and inhibits the activity of CDK2, 5 and 9, which
leads to inhibition of CDK2, 5 and 9-dependent cellular pathways, downregulation of
genes involved in the pro-survival pathway, prevention of the activation of DNA double-strand
break repair pathways, and induction of both cell cycle arrest and apoptosis. This
inhibits the proliferation of CDK2/5/9-overexpressing tumor cells. In addition, CYC065
protects hematopoietic stem and progenitor cells (HSPCs), prevents myelosuppression,
and preserves the function of the bone marrow. CDKs are serine/threonine kinases involved
in the regulation of the cell cycle and may be overexpressed in certain cancer cell
types; they play key roles in tumor cell proliferation, the regulation of transcription,
and DNA damage repair.;
UNII : YET2XNU791;
InChIKey : DLPIYBKBHMZCJI-WBVHZDCISA-N;
CAS number : 1070790-89-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1070790-89-4
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : CYC065;
NCI Metathesaurus CUI : CL498266;
Origin ID : C123902;
UMLS CUI : C5418168;
Currated CISMeF NLP mapping
- CYC065 [MeSH Supplementary Concept]
- Semantic type(s)
- UMLS correspondences (same concept)
- CYC065 [MeSH Supplementary Concept]
- chemical_or_drug_affects_gene_product
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
